A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Early-Line Treatment in Subjects with Multiple Myeloma

Trial Identifier: D831EC00001
Sponsor: AstraZeneca
Start Date: July 2025
Primary Completion Date: June 2028
Study Completion Date: June 2028

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
US, CA Duarte, CA, US, 91010
US, CO Denver, CO, US, 80218
US, MO Saint Louis, MO, US, 63110
US, NY New York, NY, US, 10016
US, TN Nashville, TN, US, 37203
US, TX Dallas, TX, US, 75235